The Health Insurance Bureau responded with 700,000 "sky-high medicines".

According to the application, Ouyang Chunlan requested that the procurement contract for the introduction of Nosinasi sodium injections be made public, the basis for pricing and pricing of domestic sales prices, and information on the quantity and distribution of Nosinas sodium injection stocks.
the disease treated with a 700,000-a-shot Nosinasi sodium injection? It is reported that the Nosinasi sodium injection was developed by Yan Jian company, on December 23, 2016 was first approved in the United States, is the world's first precision targeted treatment for spinal muscular dystrophy.
, the drug was approved in the European Union, Brazil, Japan, South Korea, Canada and other countries for the treatment of spinal muscular dystrophy.
April 28, 2019, Nosinasi sodium injection was launched in China for the treatment of 5qSMA and became the first drug in China to treat spinal muscular dystrophy.
of 1/6000-1/10000 infant genetic diseases Public data show that spinal muscular dystrophy (Spinal Muscular Atrophy, SMA) is a rare genetic neuromuscular disease, the incidence rate in newborns is about 1/6000-1/10000, also known as "infant genetic disease killer."
sam is classified as SMA-I, TYPE II, Type III and Type IV, depending on the age of oncology and the availability of exercise mileage, and most children with SMA-I cannot survive to the age of two without treatment.
called it a rare disease because it is unfamiliar to the vast majority of people.
2016 article found that the number of SMA patients in the country was estimated at more than 30,000, according to a 2016 paper on spinal muscular dystrophy.
in different countries, the definition of rare diseases is different because of differences in factors such as population base.
under the Rare Diseases Act, passed by the U.S. Congress in 2002, any disease or condition affecting less than 200,000 people in the United States, or an average of one case per 1,500 people, can be classified as rare.
The EU's definition of rare diseases also includes factors other than morbidity, such as "life-threatening, or chronic debilitating diseases, whose prevalence is so low that joint efforts are needed to overcome them".
The so-called sky-high price, from an industrial point of view, public information shows that spinraza is also expensive to treat in the United States, priced at $125,000 per needle, requiring six injections in the first year, about $750,000 in treatment, and halving the cost the next year to $375,000.
, the price of Nosinas sodium injections in China is 697,000 yuan per unit, which is a completely out-of-the-way drug and has set a new record for the price of a Drug in China.
On the price of nosinasi sodium injection, August 5, the National Health Insurance Administration letter office staff said that the price of nosinasi sodium injection is self-pricing by pharmaceutical companies, so the price of the drug in each country there is a certain difference, "in addition to the raw materials of the drug, research and development costs, pharmaceutical companies will also consider the issue of profits, coupled with the drug is currently in the domestic market monopoly situation, the price has been high."
", the State Drug Administration also said that although the State Drug Administration through the priority review and approval process approved the use of this drug imported for treatment, but it does not have drug pricing power.
if we look at it from the point of view of pharmaceutical companies, how should we understand the price? On the one hand, at present, the only drug in the country to treat spinal muscular dystrophy is nosine sodium injection, which was a non-treatable condition before the nosine sodium injection was available.
, on the other hand, new drug research and development has long been considered a high-risk, high-yielding activity, and the industry generally believes that the development of a new drug will take a decade and cost a billion dollars.
addition, because the drug is still a rare disease, compared to common chronic diseases, the number of cases is very small, there are not enough patients to dilute the cost, invisibly also pushed up the price a single patient needs to pay.
, the other two drugs that treat SMA, Roche's Risdiplam and Novarma's Zolgensma, are priced at an alarming price.
, Zolgensma is the most expensive drug in Japan at 167.07 million yen (about 11.02 million yuan), Kyodo news agency reported.
Thanks to the priority review and approval, it is worth noting that although the sky-high price of nearly 700,000 is awful, but it must also be seen that thanks to a series of efforts by the relevant departments, the speed of new drugs on the domestic market is accelerating, at least for the time being, for some clinically urgently needed new drugs, the use of the problem has been solved.
December 2017, the former State Administration of Food and Drug Administration issued the Opinions on Encouraging Drug Innovation for Priority Review and Approval, which clearly stated that rare diseases should be included in the scope of priority review.
September 2018, Nosinas sodium injections as a new drug for the treatment of rare diseases that have been listed overseas and are clinically urgently needed were included in the priority review and approval process by the State Drug Administration.
On October 31, 2018, the State Drug Administration, together with the National Health and Safety Commission, issued the "Clinical urgent need for overseas new drug review and approval procedures" and declaration information requirements, the establishment of a special channel for clinical urgent need for overseas listing of new drug review and approval, rare disease treatment drugs and other foreign new drugs respectively committed to 3 months, 6 months to review.
2019, the Nosinasi sodium injection was approved in China through the priority review and approval process and was listed in Shanghai on April 28, 2019.
nosinasitic sodium injection appeared in the 2019 Drug Review Report released by the National Drug Administration.
the Review Report, the State Drug Administration said that the listing of sodium nosine injection has effectively solved the urgent need for clinical drugs for spinal muscular dystrophy in China.
In 2019, China's Drug Review Center approved a total of 16 drugs for the treatment of rare diseases, clinically urgently needed drugs, an increase of 60% over 2018, and all completed the review within the prescribed time limit, greatly reducing the clinical urgent need for new drugs overseas market time gap in China.
it's useful, and it's hoped that a seemingly contrasting set of figures in the media will stung the nerves of some netizens - A$41 and Rmb700,000.
fact, behind these two numbers are two different concepts.
a statement today, Mr. Yu said drug prices and out-of-the-money costs for patients after drug reimbursement are two completely different concepts.
According to public information on the Australian Pharmaceutical Benefit Scheme - PBS website, nosinasi sodium injections have been incorporated into the drug benefit scheme, with government-purchased drugs costing A$110,000 and patients paying A$41 out-of-the-way.
A$41 is not the price of a drug in Australia for a nosinasi sodium injection.
as of June 30, 2020, Nosinas sodium injections have been approved in 50 countries and territories around the world and reimbursed in more than 40 countries and territories, including Australia.
, the Nosinasi sodium injection is not a health insurance drug.
according to national regulations, drugs participating in the 2019 National Health Care Negotiations must be approved by December 31, 2018.
sodium injection was approved in February 2019 and is not eligible to participate in the 2019 National Health Care Negotiations, and therefore did not participate in the 2019 National Health Care Negotiations.
Said it has launched a number of aid donations for SMA patients - on May 31, 2019, the China Primary Health Care Foundation announced the official launch of the SMA Patient Assistance Program, which is donated by Yan Jian, which helps SMA patients save about two-thirds of their first year of treatment at their own expense, and then save about half of their annual treatment costs compared to full out-of-the-fund costs.
, more than 80 SMA patients across the country have received medication with the help of aid programs.
the same time, Yan Jianbi has been actively communicating with relevant departments of national and local governments, calling for the establishment of a multi-party co-payment mechanism to further improve the drug access of SMA patients in China.
last year's national health-care negotiations, 150 drugs, and eventually 97 successful and all included in the health-care list of Class B drugs.
a number of highly recognized, newly marketed and clinically valuable drugs, such as cancer, rare diseases, chronic diseases and children's medications.
The National Health Insurance Administration also said that the follow-up will explore the establishment of a dynamic adjustment mechanism of the health insurance catalog, comprehensive clinical needs, the affordability of health insurance funds and the price will of enterprises, and re-negotiate prices, the appropriate drugs into the health insurance catalog.
should say that the national health care negotiations, on the one hand, released a clear signal in support of innovative drugs, on the other hand, also made noble drugs into civilian drugs, greatly reducing the burden on patients.
But it must also be noted that China's large population, complex and diverse disease types, with the acceleration of the aging of the population, the ability to pay for health insurance funds is also facing challenges, under a limited plate, to judge which groups of drug use and health needs should be protected, in fact, is not an easy problem.
.